FindTrial
Sign In

The postoperative outcome of esophageal cancer: oral Tegafur Gimeracil of 6 cycles VS 12 cycles

The postoperative outcome of esophageal cancer: oral Tegafur Gimeracil of 6 cycles VS 12 cycles

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003657
Enrollment
Unknown
Registered
2013-10-04
Start date
2013-10-07
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

6 cycles:oral Tegafur Gimeracil of 6 cycles
12 cycles:oral Tegafur Gimeracil of 12 cycles

Sponsors

Xijing hospital, Fourth Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with esophageal cancer (Aged from 18 to 75); 2. No chemotherapy or radiotherapy was performed before operation; 3. understood the experiment, informed consent.

Exclusion criteria

Exclusion criteria: 1. patients with metastatic disease.

Design outcomes

Primary

MeasureTime frame
Nausea;vomiting;—

Secondary

MeasureTime frame
survival;—

Countries

China

Contacts

Public ContactLiu Hong

Xijing hospital, Fourth Military Medical University

hongliu180@126.com+86 13709284513

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026